EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mocetinostat Ameliorates Pathological Cardiac Hypertrophy via Suppression of Ferroptosis Through Nrf2 Pathway

Jingyu Li, Hanrui Sun, Jiabin Zhou, Jiayu Shi, Peng Xu, Chen Wang, Chuchu Chen, Pengyang Gu, Xinglin Wang, Qing Gong, Anzhen Xu, Yanbo Li und 1 weitere

Die Pharmazie · 28.05.2026 · 81 (5)

DOI: 10.31083/pharmazie51659 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 28.05.2026. Verfasst von Jingyu Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, Nantong University, 226000 Nantong, Jiangsu, China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Ferroptosis, Cardiomegaly, Benzamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Affiliated Hospital of Nantong University Research Physician Development Fund, Postgraduate Research & Practice Innovation Program of Jiangsu Province in 2023.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective:Histone deacetylase 1 (HDAC1) exacerbates ventricular remodeling and heart failure by promoting myocardial peroxidative damage. Thus, this study aimed to investigate whether the HDAC1 inhibitor mocetinostat alleviates pathological cardiac hypertrophy via suppressing ferroptosis and to elucidate the potential mechanisms involving the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway.Methods:Primary cardiomyocytes were stimulated with phenylephrine (PE) to induce hypertrophy and ferroptosis in vitro, with or without mocetinostat treatment. The Nrf2 inhibitor ML385 was used to verify pathway specificity. In vivo, a mouse model of pressure-overload-induced cardiac hypertrophy was established using a transverse aortic constriction (TAC)-induced approach. Mocetinostat was administered to evaluate its therapeutic effects. Ferroptosis markers including lipid peroxidation, iron accumulation, and levels of ferroptosis-related proteins, were assessed. The acetylation and nuclear translocation of Nrf2, as well as the expression of the associated downstream targets (Solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase 4 (GPX4), ferroportin, ferritin heavy chain 1 (FTH1), heme oxygenase-1 (HO-1)), were analyzed.Results:Mocetinostat treatment significantly ameliorated PE-induced cardiomyocyte hypertrophy and ferroptosis in vitro and attenuated TAC-induced cardiac hypertrophy and fibrosis in vivo. Mechanistically, mocetinostat facilitated Nrf2 acetylation and promoted Nrf2 nuclear translocation, leading to the transcriptional activation of downstream antioxidant targets and subsequent inhibition of lipid peroxidation. The protective effects of mocetinostat were abrogated by the Nrf2 inhibitor ML385.Conclusion:This study demonstrates that mocetinostat attenuates pathological cardiac hypertrophy by inhibiting ferroptosis through activation of the Nrf2 pathway . These findings indicate the potential of mocetinostat as a therapeutic strategy for delaying heart failure progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2FerroptosisCardiomegalyBenzamidesAnimalsMaleMyocytes, CardiacMiceMice, Inbred C57BLDisease Models, AnimalSignal TransductionHistone Deacetylase InhibitorsLipid PeroxidationCells, Cultured

Stichwörter der Autor:innen

ferroptosishistone deacetylase inhibitorsmyocardial hypertrophynuclear factor erythroid 2-related factor 2

Substanzen

NF-E2-Related Factor 2Nfe2l2 protein, mouseHistone Deacetylase InhibitorsBenzamides

Autor:innen und Institutionen

  • Medical School, Nantong University, 226000 Nantong, Jiangsu, China.
  • Department of Cardiology, Affiliated Hospital of Nantong University, 226000 Nantong, Jiangsu, China.
  • Department of Cardiovascular Medicine, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, 214023 Wuxi, Jiangsu, China.
  • Department of Cardiology, Nantong Sixth People's Hospital, 226000 Nantong, Jiangsu, China.
  • Department of Cardiology, Jiangyin Hospital of Traditional Chinese Medicine, 214400 Wuxi, Jiangsu, China.
  • Department of Cardiology, Fujian Medical University Union Hospital, 350001 Fuzhou, Fujian, China.

Förderung

  • Affiliated Hospital of Nantong University Research Physician Development Fund
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province in 2023

Zitieren

APA

Li, J., Sun, H., Zhou, J., Shi, J., Xu, P., Wang, C., Chen, C., Gu, P., Wang, X., Gong, Q., Xu, A., Li, Y., & Lu, Q. (2026). Mocetinostat Ameliorates Pathological Cardiac Hypertrophy via Suppression of Ferroptosis Through Nrf2 Pathway. Die Pharmazie, 81(5). https://doi.org/10.31083/pharmazie51659

Vancouver

Li J, Sun H, Zhou J, Shi J, Xu P, Wang C, et al. Mocetinostat Ameliorates Pathological Cardiac Hypertrophy via Suppression of Ferroptosis Through Nrf2 Pathway. Die Pharmazie. 2026;81(5). doi:10.31083/pharmazie51659

BibTeX
@article{Li2026,
  author = {Li, Jingyu and Sun, Hanrui and Zhou, Jiabin and Shi, Jiayu and Xu, Peng and Wang, Chen and Chen, Chuchu and Gu, Pengyang and Wang, Xinglin and Gong, Qing and Xu, Anzhen and Li, Yanbo and Lu, Qi},
  title = {Mocetinostat Ameliorates Pathological Cardiac Hypertrophy via Suppression of Ferroptosis Through Nrf2 Pathway},
  journal = {Die Pharmazie},
  year = {2026},
  volume = {81},
  number = {5},
  doi = {10.31083/pharmazie51659}
}
Kostenlos starten →